KCM
UTHR icon

Key Capital Management’s United Therapeutics UTHR Stock Holding History

Key Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$3.56K – 811
2026
Q1 		$3.56K Buy
+6
New +$2.99K ﹤0.01% 436

Other funds holding UTHR

AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Key Capital Management's UTHR Position: Q2 2026 in Review

Key Capital Management sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 6 shares — an estimated $3.56K sold.

Key Capital Management first reported a position in UTHR in Q1 2026 and held it in 1 quarter. The position peaked at $3.56K in Q1 2026. 379 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Key Capital Management reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Key Capital Management sold 6 United Therapeutics shares in Q2 2026, an estimated $3.56K.
  • Key Capital Management first reported a position in United Therapeutics in Q1 2026 and held it in 1 quarter.
  • Key Capital Management's United Therapeutics position peaked at $3.56K in Q1 2026.
  • 379 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Key Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.